News
HIV, CVS Health and Gilead
Digest more
CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...
Investing.com - Gilead Sciences (NASDAQ: GILD) stock faces a temporary setback after CVS Caremark declined to add its HIV prevention drug Yeztugo to commercial formularies, according to a Reuters ...
A source familiar with the situation suggested that Gilead is still negotiating with CVS over Yeztugo, a twice-yearly injection with a U.S. list price of more than $28,000 a year.
CVS Health, the parent of PBM juggernaut CVS Caremark, won’t presently add Gilead’s twice-yearly pre-exposure prophylaxis (PrEP) drug Yeztugo to its commercial plans or Affordable Care Act ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback